Clinical Trial

Systems Biological Analysis of Immune Responses to RSV Vaccine

Study acronym: RSV SB
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to characterize the immune response to the FDA-approved mRNA-based RSV vaccine in adults ≥60 years of age, using a systems biology approach. The study aims to generate high-resolution immunologic and systems biology data following vaccination to identify early biomarkers of response and gain mechanistic insight into host immunity.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07 -> 2027-01 2026-08-13
minor Completion pushed: 2026-07 -> 2027-01 2026-08-13
Trial Details
NCT Number NCT07185399
Lead Sponsor Emory University
Collaborators: Open Philanthropy
Conditions Respiratory Syncytial Virus (RSV)
Enrollment 14 participants
Start Date 2025-10-13
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-12